Prevention of intravenous contrast-induced nephropathy in hospital inpatients

Critical Pathways in Cardiology

Volumn 7, Issue 1, 2008, Pages 1-4

  Kakkar, Rahul ^a,c   Sobieszczyk, Piotr ^a   Binkert, Christoph A ^b   Faxon, David P ^a   Mortele, Koenraad J ^b   Singh, Ajay K ^a  

^a Department of Medicine ^*  (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Contrast nephropathy; Guidelines; Prophylaxis

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CONTRAST MEDIUM; CREATININE; DIURETIC AGENT; MANNITOL;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MORBIDITY; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; SCORING SYSTEM; ACUTE KIDNEY FAILURE; AGED; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITAL PATIENT; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION TEST; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PRIMARY PREVENTION; PROGNOSIS; REVIEW; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONTRAST MEDIA; FEMALE; GLOMERULAR FILTRATION RATE; HOSPITAL MORTALITY; HUMANS; INJECTIONS, INTRAVENOUS; INPATIENTS; KIDNEY FAILURE, ACUTE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 47149097285     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e318163f258     Document Type: Article

References (22)

1. McCullough PA, Wolyn R, Rocher LL, et al.Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.Am J Med.1997;103:368-375.
2. Rihal CS, Textor SC, Grill DE, et al.Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention.Circulation. 2002;105:2259-2264.
3. Nash K, Hafeez A, Hou S.Hospital-acquired renal insufficiency.Am JKidney Dis.2002;39:930-936.
4. Parfrey PS, Griffiths SM, Barrett BJ, et al.Contrast material- inducedrenal failure in patients with diabetes mellitus, renal insufficiency, or both.N Engl J Med.1989;320:143-149.
5. Marenzi G, Marana I, Lauri G, et al.The prevention of radiocontrastagent-induced nephropathy by hemofiltration.N Engl J Med.2003;349:1333-1340.
6. Gruberg L, Mintz GS, Mehran R, et al.The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency.J Am Coll Cardiol.2000;36:1502-1508.
7. Tumlin JA, Wang A, Murray PT, et al.Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilottrial in the prevention of contrast nephropathy.Am Heart J.2002;143:894-903.
8. Marenzi G, Lauri G, Assanelli E, et al.Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.J Am Coll Cardiol.2004;44:1780-1785.
9. Mehran R, Aymong ED, Nikolsky E, et al.A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.J Am Coll Cardiol.2004;44:1393-1399.
10. Barrett BJ, Parfrey PS.Preventing Nephropathy Induced by Contrast Medium.N Engl J Med.2006;354:379-386.
11. Moore RD, Steinberg EP, Powe NR, et al.Nephrotoxicity of high osmolality versus low-osmolality contrast media: randomized clinical trial.Radiology. 1992;182:649 -655.
12. Rudnick MR, Goldfarb S, Wexler L, et al.Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial.The Iohexol Cooperative Study.Kidney Int.1995;47:254-261.
13. Aspelin P, Aubry P, Fransson SG, et al.Nephrotoxic effects in high-risk patients undergoing angiography.N Engl JMed.2003;348:491-499.
14. Trivedi HS, Moore H, Nasr S, et al.A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity.Nephron Clin Pract.2003;93:C29 -C34.
15. Mueller C, Buerkle G, Buettner HJ, et al.Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty.Arch Intern Med.2002;162:329-336.
16. Merten GJ, Burgess WP, Gray LV, et al.Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.JAMA.2004;291:2328-2334.
17. Briguori C, Airoldi F, D'Andrea D, et al.Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.Circulation.2007;115:1211-1217.
18. Nallamothu BK, Shojania KG, Saint S, et al.Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.Am J Med.2004;117:938-947.
19. Marenzi G, Assanelli E, Marana I, et al.N-acetylcysteine and contrast induced nephropathy in primary angioplasty.N Engl JMed.2006;354:2773-2782.
20. Thomsen HS.Guidelines for contrast media from the European Society of Urogenital Radiology.AJR Am J Roentgenol.2003;181:1463-1471.
21. American College of Radiology.Manual on contrast media, version 5.0.Available at:
22. Alvaro A, Sarnak MJ.Radiocontrast nephropathy.Nephrol Rounds.2006:8 -7.Available at: